TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31678728

Group type: EXPERIMENTAL
Intervention: Gestational cadmium exposure (measured as blood cadmium concentration)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Coal stove density (measured as density of coal-burning stoves within 5000 m of participants' apartments)
Number of subjects: 374
Study: 29626378

Group type: EXPERIMENTAL
Intervention: Gardening activities (plant task)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control task (without plants)
Number of subjects: 40
Study: 26711545

Group type: EXPERIMENTAL
Intervention: Hypnosis combined with topical oropharyngeal anaesthesia (HYP group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Topical oropharyngeal anaesthesia only (CTRL group)
Number of subjects: 98
Study: 25218906

Group type: COMPARATOR
Intervention: Olaparib monotherapy (400 mg twice daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of cediranib (30 mg daily) and olaparib (200 mg twice daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination therapy (cediranib plus olaparib)
Number of subjects: 90
Study: 21618664

Group type: EXPERIMENTAL
Intervention: fMRI investigation during speed-accuracy strategy switching
Number of subjects: 0
Study: 21175312

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg orally twice daily
Number of subjects: 5407

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg subcutaneously every 24 hours
Number of subjects: 5407

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5407

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 5407
Study: 17427536

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone tablet (Glista)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 30 mg pioglitazone tablet (Actos)
Number of subjects: 24
Study: 15580607

Group type: EXPERIMENTAL
Intervention: Pergolide 25 mug twice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 12530048

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/mq weekly on days 1 and 8, followed by a 2-week rest; Cisplatin 80 mg/mq on day 2 of each 28-day cycle.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin regimen
Number of subjects: 50
Study: 9464215

Group type: EXPERIMENTAL
Intervention: Fluoxetine 10 mg/day for 1 week
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for 5 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for an additional 2 weeks
Number of subjects: 15
Study: 7710018

Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg.kg‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Thiopentone 5.0 mg.kg‐1.min‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 8
Study: 2708881

Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 186

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 186
Study: 795696

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 250 mg of lidocaine
Number of subjects: 246

Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 246
Study: 31915807

Group type: EXPERIMENTAL
Intervention: Presatovir 200 mg every 4 days for 5 doses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31061244

Group type: EXPERIMENTAL
Intervention: Small-sized businesses (less than 50 employees)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Medium-sized businesses (50-99 employees)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Large-sized businesses (100 or more employees)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Small-sized businesses
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Businesses overall
Number of subjects: 188
Study: 30408713

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 54
Study: 27864255

Group type: EXPERIMENTAL
Intervention: Tailored printed feedback summarising identified health needs and recommended self-management actions.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Tailored printed feedback on identified health needs after follow-up interview.
Number of subjects: 360
Study: 25210473

Group type: EXPERIMENTAL
Intervention: Fasinumab 0.1 mg/kg
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Fasinumab 0.3 mg/kg
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 22362063

Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (0.3 g/kg body weight per day) supplemented with ketoanalogues
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-protein diet (0.6 g/kg body weight per day)
Number of subjects: 32
Study: 20622031

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone propionate (SFP), 50/100 μg twice a day
Number of subjects: 158

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP), 200 μg twice a day
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone propionate (SFP)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone propionate (SFP) and Fluticasone propionate (FP)
Number of subjects: 158
Study: 18001568

Group type: EXPERIMENTAL
Intervention: Aspheric intraocular lens (Tecnis IOL)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Spherical intraocular lens
Number of subjects: 169
Study: 16363616

Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Doppler examinations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Scintigraphic evaluation
Number of subjects: 40
Study: 12932605

Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretics (PSDs)
Number of subjects: 6797

Group type: COMPARATOR
Intervention: Non-potassium-sparing diuretics (non-PSDs)
Number of subjects: 6797

Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretics (PSDs) with or without non-potassium-sparing diuretics (non-PSDs)
Number of subjects: 6797
Study: 10392654

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nondepressed patients
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 85
Study: 8934600

Group type: EXPERIMENTAL
Intervention: Proposed method for comparing two clustered samples of censored data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1910082

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7036278

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vincristine, cyclophosphamide, and 5‐fluorouracil once a month for 12 months)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy (150 mg BCG once a week for 1 year)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No complementary treatment (control group)
Number of subjects: 82
Study: 31020541

Group type: EXPERIMENTAL
Intervention: Oral Bifidobacterium tetravaccine tablets (Live) for 2 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 120
Study: 30119636

Group type: EXPERIMENTAL
Intervention: Menstrual cups provided to girls with training and guidance on use, puberty education, and instructions for menstrual hygiene.
Number of subjects: 192
Study: 26782957

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 181

Group type: COMPARATOR
Intervention: neoadjuvant chemotherapy (nCT)
Number of subjects: 181
Study: 25364994

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ongoing education and support
Number of subjects: 105
Study: 22058190

Group type: EXPERIMENTAL
Intervention: Front-loaded counseling (FL)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Weekly counseling
Number of subjects: 278
Study: 20625319

Group type: EXPERIMENTAL
Intervention: More intense antihypertensive treatment
Number of subjects: 9711

Group type: COMPARATOR
Intervention: Less intense antihypertensive treatment
Number of subjects: 9711

Group type: EXPERIMENTAL
Intervention: Higher baseline systolic BP and smoking
Number of subjects: 9711

Group type: EXPERIMENTAL
Intervention: Higher cholesterol
Number of subjects: 9711

Group type: EXPERIMENTAL
Intervention: Electrocardiographic left-ventricular hypertrophy and isolated systolic hypertension
Number of subjects: 9711
Study: 17638307

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape surgery (TVT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no treatment for 6 months)
Number of subjects: 69
Study: 15985160

Group type: EXPERIMENTAL
Intervention: Focused discussions on household cost-benefit equations in intervention communities
Number of subjects: 3344

Group type: COMPARATOR
Intervention: Usual health promotion activities relating to immunisation in control communities
Number of subjects: 3344
Study: 12409741

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 37
Study: 10374554

Group type: EXPERIMENTAL
Intervention: Preoperative selective vascular chemotherapy with routine quantity of FAM
Number of subjects: 82
Study: 8195821

Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg/day orally for 6 months
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (ALS controls)
Number of subjects: 111
Study: 3035879

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (0.5 microgram daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Vitamin D3 (400 IU daily)
Number of subjects: 76
Study: 31293057

Group type: EXPERIMENTAL
Intervention: Tele‐MAST videoconferencing program
Number of subjects: 148

Group type: COMPARATOR
Intervention: standard care from a cancer counselling service
Number of subjects: 148
Study: 28730331

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exoskeleton
Number of subjects: 62
Study: 28186943

Group type: EXPERIMENTAL
Intervention: Picture booklet intervention used with a trained researcher and a carer present, used at least twice over 20 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual (control group) with a booklet provided at the end of the study.
Number of subjects: 40
Study: 25115507

Group type: EXPERIMENTAL
Intervention: Caffeine (split dose 2 × 3 mg kg(‐1))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 6
Study: 21626050

Group type: EXPERIMENTAL
Intervention: Erythromycin breath test (EBT) with IV C(14)[N‐methyl]‐erythromycin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antipyrine clearance test (ACL) with oral antipyrine 10 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m(2)/3‐weekly or 35 mg/m(2)/weekly)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Docetaxel weekly patients
Number of subjects: 20
Study: 19781877

Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 113
Study: 17164029

Group type: EXPERIMENTAL
Intervention: Specific communication techniques delivered by GPs focused on offering a physical explanation and approaching sensitive topics indirectly.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard Goldberg reattribution technique used by control GPs.
Number of subjects: 156
Study: 15697064

Group type: EXPERIMENTAL
Intervention: Pneumatic tyres at 100% inflation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pneumatic tyres at 50% inflation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Solid tyres
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pneumatic tyres at 75% inflation
Number of subjects: 15
Study: 11163814

Group type: EXPERIMENTAL
Intervention: Ganirelix acetate
Number of subjects: 313

Group type: COMPARATOR
Intervention: Leuprolide acetate
Number of subjects: 313
Study: 9784887

Group type: EXPERIMENTAL
Intervention: Simulators (20 individuals)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non‐simulators (20 individuals)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Patients (25 individuals)
Number of subjects: 65
Study: 8055275

Group type: EXPERIMENTAL
Intervention: Cytologic screening examinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiographic screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery for stage I lung cancers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term annual screening of a high-risk population
Number of subjects: 0
Study: 2841552

Group type: EXPERIMENTAL
Intervention: Running exercise at 92% of maximal oxygen consumption
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Running exercise at 98% of maximal oxygen consumption
Number of subjects: 10
Study: 7962679

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 153

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 153
Study: 384738

Group type: EXPERIMENTAL
Intervention: PEEP ventilation (1 kPa or 10 cmH2O)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation without PEEP (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (PEEP and control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PEEP ventilation and control
Number of subjects: 40
Study: 31308037

Group type: EXPERIMENTAL
Intervention: Thymalfasin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (anti-infection treatment)
Number of subjects: 80
Study: 25475768

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorohexidine gel (Group 2)
Number of subjects: 301

Group type: COMPARATOR
Intervention: 0.12% Chlorohexidine rinse (Group 1)
Number of subjects: 301
Study: 23958160

Group type: EXPERIMENTAL
Intervention: Drainage in cavities group (DC, n = 32)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional drainage group (CD, n = 36)
Number of subjects: 68
Study: 21184640

Group type: EXPERIMENTAL
Intervention: 7.5 x 140‐mm iliac screw
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 9.5 x 140‐mm iliac screw
Number of subjects: 10

Group type: COMPARATOR
Intervention: Supraacetabular trajectory
Number of subjects: 10

Group type: COMPARATOR
Intervention: Anterior inferior iliac spine (AIIS) trajectory
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Depth > 80 mm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Depth ≤ 80 mm
Number of subjects: 10
Study: 19339319

Group type: EXPERIMENTAL
Intervention: B‐CTI (brief three‐month critical time intervention)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study: 17405770

Group type: EXPERIMENTAL
Intervention: Evolving Myocardial Infarction (EMI)
Number of subjects: 8309

Group type: COMPARATOR
Intervention: Myocardial Infarction (MI)
Number of subjects: 8309
Study: 16291100

Group type: EXPERIMENTAL
Intervention: Congenital lumbar stenosis group (20 patients)
Number of subjects: 40
Study: 11571096

Group type: EXPERIMENTAL
Intervention: 1.25 mg oral methyltestosterone (meT) in combination with 0.625 mg oral esterified estrogen (E)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 0.625 mg oral esterified estrogen (E) alone
Number of subjects: 35
Study: 9262254

Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aspirin 324 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aspirin 40.5 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 7898011

Group type: EXPERIMENTAL
Intervention: Individual approach to immune correction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: T‐ and B‐lymphocyte systems
Number of subjects: 57
Study: 3311133

Group type: EXPERIMENTAL
Intervention: Dorsal position
Number of subjects: 58

Group type: COMPARATOR
Intervention: 15 degrees lateral tilt position
Number of subjects: 58
Study: 30557879

Group type: EXPERIMENTAL
Intervention: Short-term steroid regimen (prednisolone 0.8-1.0 mg/kg/day for 4-6 weeks, then 0.5-0.6 mg/kg/alternate day for 4 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional steroid administration (control group, n = 140)
Number of subjects: 35
Study: 28746934

Group type: EXPERIMENTAL
Intervention: Salvianolate
Number of subjects: 484
Study: 22821285

Group type: EXPERIMENTAL
Intervention: Selenium intake (μg/day/1,000 kcal)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Calcium intake (mg/day/1,000 kcal)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Percentage of total energy from dairy products
Number of subjects: 39
Study: 21535123

Group type: EXPERIMENTAL
Intervention: One-step screening for gestational diabetes
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Two-step screening for gestational diabetes
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Antenatal testing initiation for medication-treated gestational diabetes
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Antenatal testing initiation for diet-treated gestational diabetes
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Comfort in treating non-pregnant women with Type 2 diabetes
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Screening for Type 2 diabetes post-delivery
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Use of glibenclamide (glyburide)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Caesarean section based on fetal weight
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Initiating exercise post-delivery
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Checking 2-h postprandial glucose levels
Number of subjects: 152
Study: 18692175

Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg, titratable to 30 or 60 mg) once daily for 30 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16442328

Group type: EXPERIMENTAL
Intervention: Low and stable fibrillatory frequency
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low exponential decay
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fibrillation amplitude
Number of subjects: 50

Group type: COMPARATOR
Intervention: Complexity measures
Number of subjects: 50
Study: 12185505

Group type: COMPARATOR
Intervention: Conventional chemotherapy with CEOP-Bleo (cyclophosphamide 750 mg/m(2), vincristine 1.4 mg/m(2), prednisone 40 mg/m(2), epirubicin 70 mg/m(2), and bleomycin 10 mg/m(2)) every 21 days for six cycles followed by radiotherapy (35-45 Gy, mean 38 Gy)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy with mega CEOP-Bleo (cyclophosphamide 1000 mg/m(2), epirubicin 120 mg/m(2), vincristine, prednisone, and bleomycin at the same doses) every 21 days for six cycles followed by radiotherapy (35-45 Gy, mean 38 Gy)
Number of subjects: 68
Study: 10418699

Group type: EXPERIMENTAL
Intervention: Bright white light (2500 lux)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Infrared light (0.18 lux)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no light treatment)
Number of subjects: 38
Study: 8618810

Group type: EXPERIMENTAL
Intervention: Haemodialysis with cuprophan dialyser used first time
Number of subjects: 42

Group type: COMPARATOR
Intervention: Haemodialysis with cuprophan dialyser used more than three times
Number of subjects: 42
Study: 1675518

Group type: EXPERIMENTAL
Intervention: Topical PUVA
Number of subjects: 15

Group type: COMPARATOR
Intervention: UVA
Number of subjects: 15
Study: 6947693

Group type: EXPERIMENTAL
Intervention: Psychological testing for motivation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Specific Orthodontics Construct of Cooperation (SOCC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Perio-Orthodontic Construct of Cooperation (POCC)
Number of subjects: 70
Study: 28749158

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy treatment (TF-CBT-anger)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 78
Study: 27376410

Group type: EXPERIMENTAL
Intervention: MammoMARK™
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HydroMARK(®)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SecurMark(®)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MammoStar™
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All markers
Number of subjects: 80
Study: 24755139

Group type: EXPERIMENTAL
Intervention: 3 g RBEP (rice bran exo‐biopolymer)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 3 g placebo
Number of subjects: 80
Study: 22922813

Group type: EXPERIMENTAL
Intervention: Supplementary ultrafiltration (sUF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Regular hemodialysis (rHD)
Number of subjects: 26
Study: 20384669

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Glucose solution
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 19227650

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with natural rubber latex (NRL) for 3 years
Number of subjects: 12
Study: 15948087

Group type: EXPERIMENTAL
Intervention: Pedometer adherence group (n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-adherence group (n = 18)
Number of subjects: 38
Study: 12559481

Group type: EXPERIMENTAL
Intervention: Active rTMS (N=12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham treatment (N=9)
Number of subjects: 21
Study: 10075387

Group type: EXPERIMENTAL
Intervention: Blacks in Birmingham with lower education level
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Whites in Birmingham with lower education level
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Blacks with lower education level in both cities
Number of subjects: 435

Group type: COMPARATOR
Intervention: Whites
Number of subjects: 435
Study: 7677473

Group type: EXPERIMENTAL
Intervention: Sealed with fibrin glue
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reinforced with pledgets
Number of subjects: 36
Study: 2167800

Group type: EXPERIMENTAL
Intervention: Oral frusemide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Desamino‐D‐arginine‐vasopressin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Water loading
Number of subjects: 14